The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.
Horizon: Validation of an improved method for rapid characterization of protein aggregates in biologic drugs for increased quality and safetySBC: OPTOFLUIDICS, INC. Topic: NA
Optofluidics and the University of Delaware propose to complete the development of the Horizon technology and carry out validation via a comprehensive multi-site study. The technology is a subvisible particle analyzer pioneered during Phase I. The technology is designed to fill two critical gaps in biopharmaceutical product development: (1) Scientists can count and image particles with current too ...SBIR Phase II 2017 Department of CommerceNational Institute of Standards and Technology
Protein Qspec: An Improved Method for Rapid Characterization of Protein Aggregates in Biologic Drugs for Increased Quality and SafetySBC: OPTOFLUIDICS, INC. Topic: 90201
Optofluidics will develop Protein Qspec, a new particle analysis QC instrument designed to characterize protein aggregates in biologic drugs. The primary concern for this class of therapeutics is that they can elicit an immune response from patients who develop anti-drug antibodies which can eliminate the therapeutic benefit. The presence of particulate matter, in these therapeutics (e.g. shed gla ...SBIR Phase I 2016 Department of CommerceNational Institute of Standards and Technology